Pharmaceutical company Amneal Pharmaceuticals Inc (NYSE:AMRX) reported on Friday the receipt of the Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (FDA) for the generic Fluphenazine Hydrochloride Tablets USP in 1mg, 2.5mg, 5mg and 10mg for treatment of schizophrenia.
The company added that the Fluphenazine Hydrochloride is the generic version of Prolixin for treatment of schizophrenia.
Effective immediately, the company has initiated commercialization activities of generic Fluphenazine Hydrochloride across all dosages.
In conjunction, the US annual sales for Fluphenazine Hydrochloride Tablets for the 12 months ended May 2020 were approximately USD143m, according to IQVIA, a leading healthcare data and analytics provider.
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data